跳至主要内容
临床试验/EUCTR2012-003418-15-AT
EUCTR2012-003418-15-AT进行中(未招募)1 期

Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial.

Medizinische Universität Wien0 个研究点目标入组 96 人开始时间: 2012年11月9日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
96

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Diagnosis of multiple sclerosis (relapsing remitting, progressive
  • courses) according to McDonalds criteria.
  • Age > 18years
  • Fatigue as measured by Fatigue Severity Scale
  • Signed informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 36

排除标准

  • Known allergy or hypersensitivity to Methylphenidate or any of its
  • ingredients.
  • Marked anxiety, tension and agitation.
  • Patients with glaucoma or hyperthyreodism.
  • Patients with motor-tics, a family history or diagnosis of Tourette´s
  • Treatment with monoamine oxidase inhibitors, also within a
  • minimum of 14 days following discontinuation (hypertensive crisis may result).
  • Phaeochromocytoma.
  • Pre-existing cardiovascular disorders including severe hypertension, angina, arterial occlusive disorder, heart failure, haemodynamically significant congenital heart disease,
  • cardiomyopathies, myocardial infarction, potentially lifethreatening
  • arrhythmias and channelopathies.
  • History of drug dependence or alcoholism.
  • History of seizures.
  • Severe psychiatric disorders.
  • Pregnant women or females of childbearing potential who want to become pregnant within the study period.
  • Change of any medication treatment <8 weeks before starting the study
  • Participation in any other clinical trial at the same time

研究者

相似试验